Raymond James Financial
RARE icon

Raymond James Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Raymond James Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Sell
24,237
-554
-2% -$13.8K ﹤0.01% 4154
2026
Q1 		$519K Buy
24,791
+4,940
+25% +$111K ﹤0.01% 4317
2025
Q4 		$457K Sell
19,851
-4,706
-19% -$155K ﹤0.01% 4330
2025
Q3 		$739K Sell
24,557
-5,875
-19% -$176K ﹤0.01% 3872
2025
Q2 		$1.11M Buy
30,432
+9,295
+44% +$335K ﹤0.01% 3509
2025
Q1 		$765K Sell
21,137
-637
-3% -$26.5K ﹤0.01% 3670
2024
Q4 		$916K Buy
+21,774
New +$1.08M ﹤0.01% 3508

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Raymond James Financial's RARE Position: Q2 2026 in Review

Raymond James Financial reduced its Ultragenyx Pharmaceutical (RARE) stake by 2.2% in Q2 2026, selling an estimated $13.8K and leaving 24,237 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #4154.

Raymond James Financial first reported a position in RARE in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.11M in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Raymond James Financial held 24,237 shares of Ultragenyx Pharmaceutical worth $809K as of Q2 2026.
  • Raymond James Financial sold 554 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $13.8K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4154 holding.
  • Raymond James Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Ultragenyx Pharmaceutical position peaked at $1.11M in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.